

Title: Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment

Running Title: Combining sulphonylureas & insulin is effective in permanent neonatal diabetes

Authors: Shivani Misra^{*1}, Natascia Vedovato^{*2}, Edward Cliff², Elisa De Franco³, Andrew T Hattersley⁴, Frances M Ashcroft^{#2}, Nick S Oliver^{#1}

^{*}SM and NV are joint first authors. [#]FMA and NSO are joint corresponding authors

Institutions

¹ Department of Diabetes, Endocrinology & Metabolism, Imperial College London, UK

² Department of Physiology, Anatomy & Genetics, Parks Road, Oxford OX1 3PT, UK

³ Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK

⁴ Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK

Corresponding Author:

Prof. Frances M Ashcroft

Department of Physiology, Anatomy and Genetics,

University of Oxford

frances.ashcroft@dpag.ox.ac.uk

Prof. Nick S Oliver

Department of Diabetes, Endocrinology and Metabolism,

Imperial College London, UK

nick.oliver@imperial.ac.uk

Word count:

Abstract 250

Manuscript

Disclosure Summary:

The authors declare no competing conflicts of interests.

Novelty Statement

- *KCNJ11* mutations causing permanent neonatal diabetes are treated with sulphonylureas, but not all individuals are able to transfer completely from insulin to sulphonylureas
- Our data highlight that combining sulphonylurea treatment with insulin in those who are unable to fully transfer, may still lead to clinically meaningful outcomes
- We demonstrate improvements in endogenous insulin production, HbA1c, glycaemic variability and hypoglycaemia awareness
- These changes were not observed at initial doses of glibenclamide and improvements required higher sustained doses of glibenclamide
- Combining insulin and sulphonylureas should be considered in those with permanent neonatal diabetes who are not able to transfer to sulphonylurea therapy alone.

Acknowledgements

We thank Idoia Portillo (Oxford University) for technical assistance. We thank the European Union (grant no. 332620), The Wellcome Trust (grant no. 089795) and the Royal Society for support.

Key Words: Permanent neonatal diabetes; *KCNJ11* mutations; sulphonylureas

Abstract

Permanent neonatal diabetes caused by mutations in the *KCNJ11* gene may be managed with high-dose sulphonylureas. Complete transfer to sulphonylureas is not successful in all cases and can result in insulin monotherapy. In such cases, the outcomes of combining sulphonylureas with insulin have not been fully explored. We present a woman with diabetes due to a *KCNJ11* mutation, in whom combination therapy led to clinically meaningful improvements.

Case

A 22 year-old woman was found to have a *KCNJ11* mutation (G334V) following diagnosis with diabetes at 3-weeks. She was treated with insulin-pump therapy, had hypoglycaemia unawareness and suboptimal glycaemic control. We assessed the *in vitro* response of the mutant channel to tolbutamide in *Xenopus* oocytes and undertook sulphonylurea dose-titration with C-peptide assessment and continuous glucose monitoring.

In vitro studies predicted the G334V mutation would be sensitive to sulphonylurea therapy ($91 \pm 2\%$ block ($n=6$) with 0.5 mM tolbutamide). C-peptide increased following a glibenclamide test dose (5 pmol/L to 410 pmol/L). Glibenclamide dose-titration was undertaken: lower glibenclamide dose did not reduce blood glucose levels but at 1.2mg/kg/day insulin delivery was reduced to 0.1units/hour. However, when insulin was stopped, hyperglycaemia ensued. Glibenclamide was further increased (2mg/kg/day), but once-daily long-acting insulin was still required to maintain glycaemia. This resulted in improved HbA1c of 52 mmol/mol (6.9%), restoration of hypoglycaemia awareness, and reduced glycaemic variability.

Conclusion

In people with *KCNJ11* mutations causing permanent neonatal diabetes, where complete transfer is not possible, consideration should be given to dual insulin and sulphonylurea therapy.

Introduction

Permanent neonatal diabetes mellitus is a rare monogenic form of diabetes that presents within the first 6 months of life(1). Mutations in the *KCNJ11* and *ABCC8* genes, encoding the Kir6.2 and SUR1 subunits, respectively, of the pancreatic beta-cell ATP-sensitive potassium channel (K_{ATP} channel) account for 50% of cases(2,3). The K_{ATP} channel plays a key role in insulin secretion by regulating the beta-cell plasma membrane potential, and thereby insulin secretion, in response to the ambient glucose concentration(4). At low glucose levels, the channel is open, keeping the membrane hyperpolarized and inhibiting insulin release. However, when glucose levels rise, the accompanying increase in metabolically generated ATP closes the K_{ATP} channel, resulting in membrane depolarization and activation of voltage-gated calcium entry, which stimulates insulin secretion. Activating mutations in either *KCNJ11* or *ABCC8* impair the ability of the channel to respond to ATP and as a consequence, the K_{ATP} channel remains open despite of elevated plasma glucose. This impairs insulin release and results in diabetes.

Sulphonylurea drugs bind to the SUR1 subunit of the K_{ATP} channel and close it independently of ATP, thereby stimulating insulin release. They are now the therapy of choice in children with permanent neonatal diabetes caused by mutations in *KCNJ11* or *ABCC8*(5). Prior to the discovery of the genetic cause of permanent neonatal diabetes, people with the condition were treated with insulin. However, ~90% of people with neonatal diabetes due to a *KCNJ11* mutation have been able to successfully transfer from insulin to high-dose oral sulphonylurea therapy, which usually results in significant improvements in HbA1c(5–7).

Unsuccessful transfer is determined by two factors; the sensitivity of the mutant K_{ATP} channel to sulphonylurea inhibition and the duration of diabetes prior to transfer(6,7). Some mutant channels are less sensitive to sulphonylurea inhibition, and no cases with a mutation that shows <60% block of the K_{ATP} current by 0.5mM tolbutamide in *in vitro* studies, have been able to transfer. In other cases, however, where some people have been able to transfer but others with the same mutation have been unable to do so, the ability to transfer is correlated to the duration of diabetes: an earlier age at transfer is more likely to result in success(6,7).

In those who have been unable to transfer to sulphonylureas completely, variable practice is observed with some reverting to insulin monotherapy, and others remaining on a combination of sulphonylureas and insulin or other agents(6–8). The clinical benefits of remaining on combined insulin and sulphonylurea therapy have not been fully explored.

We report a case in which sulphonylurea therapy in combination with insulin treatment enabled a significant reduction in insulin dose, transition off insulin pump therapy and led to clinically meaningful improvements in HbA1c, glycaemic variability and hypoglycaemia awareness. We undertook clinical and *in vitro* studies to investigate this phenotype further and show that the inability to transfer off insulin completely should not be considered a failure if the addition of sulphonylureas to the treatment regime results in improved glycaemia.

Methods

Molecular Genetics

Genomic DNA was extracted from peripheral leukocytes using standard procedures. The coding regions and conserved splice sites of the *ABCC8* and *KCNJ11* genes were amplified by PCR and the resulting amplicons sequenced using the Big Dye Terminator Cyclor Sequencing Kit v3.1 (Applied Biosystems, Warrington, UK). The products were analysed on an ABI 3730 Capillary sequencer (Applied Biosystems, Warrington, UK) and compared to the reference sequences (NM_000525.3 and NM_000352.3) using Mutation Surveyor v3.24 software (SoftGenetics, State College, PA).

Functional Studies

We used human Kir6.2 (GenBank NM000525, with E23 and I337) and rat SUR1 (GenBank L40624). Site-directed mutagenesis of Kir6.2 was performed as described previously(6,9). Defolliculated *Xenopus laevis* oocytes were injected with 0.8ng wild-type (or mutant) Kir6.2 mRNA and 4ng SUR1 mRNA, and incubated in Barth's solution at 18°C for 1-4 days. To simulate the heterozygous state of the heterozygous phenotype, we co-injected a 1:1 mixture of mutant and wild-type Kir6.2, together with SUR1. The resulting channel population (referred to here as hetG334V) will contain a variable number of mutant subunits (between zero and four) in the Kir6.2 tetramer.

Clinical Investigations

All studies were undertaken on the clinical investigation unit. Sulphonylurea test dose and oral glucose tolerance tests were undertaken according to the Exeter team protocol(10). Briefly, following cessation of bolus insulin and a 75g oral glucose tolerance test, a test dose of ~0.1mg/kg of glibenclamide was administered. Subsequent dose titration was carried out according to the transfer protocol.

Results

Clinical Data

A 22 year-old woman of south-east Asian ethnicity was diagnosed with diabetes at the age of 3 weeks in her home country. This was assumed to be type 1 diabetes. She was delivered following a caesarian

section (breech position) at term weighing 3.2 kg. She developed normally during childhood with no delay in achieving milestones, no epilepsy and only a diagnosis of mild dyslexia. She was treated for 17 years with multiple daily injections of insulin, before commencing insulin pump therapy at the age of 18 years. She had several documented episodes of diabetic ketoacidosis during her childhood and teenage years. Neither parent or her only sibling was affected with diabetes.

Genetic data

Having moved to the UK, genetic testing for permanent neonatal diabetes was requested on the basis of her diagnosis before 6 months of age. Genetic testing revealed a heterozygous *KCNJ11* missense mutation, p.G334V (c.1001G>T), presumed to have occurred *de novo*, given absence of diabetes in either parent.

At the time of genetic testing, the woman had poor glycaemic control, impaired awareness of hypoglycaemia, background retinopathy and significant abdominal lipohypertrophy (see table 1 for baseline characteristics). There was no evidence of nephropathy or neuropathy. She required between 80-85 units of insulin per day via a pump, delivered with variable basal rates and bolus meal-time insulin. Continuous glucose monitoring (CGM) was undertaken in view of her frequent hypoglycaemia and revealed significant glycaemic variability (standard deviation 4.0 mmol/L) with hyperglycaemic excursions and frequent hypoglycaemia.

Functional studies (see below) were undertaken to determine if the Kir6.2-G334V mutant channels were sensitive to sulphonylurea inhibition, with positive results. Consequently, a glibenclamide test dose was undertaken following a day admission, as part of clinical care (see figure 1). This revealed an immediate and significant rise in C-peptide following a 5mg glibenclamide test dose, indicating the beta-cells were capable of releasing endogenous insulin. A formal glibenclamide trial was therefore undertaken using the Exeter protocol(10) (see figure 2 for a summary of the dose titration), and insulin basal rates were reduced in parallel with increasing glibenclamide doses.

Within 8 weeks of commencing treatment, she was receiving a glibenclamide dose of 20mg twice daily (0.67mg/kg/day, 40mg/day total) and her basal insulin requirements had reduced to a total basal dose of 9.6units/day via her insulin pump (0.4units/hours). Her median blood glucose, as assessed by frequent home blood glucose monitoring, was 8.4 mmol/L. Basal insulin was further reduced, but glucose levels rose to a median of 12 mmol/L. Glibenclamide was therefore increased to a dose of 70mg/day (1.2mg/kg/day in 3 divided doses of 30mg/10mg/30mg) and basal insulin was reduced to 0.1 units/hour (total basal dose 2.4units/day). At this point, her median blood glucose was 8.6 mmol/L and an attempt to stop insulin completely was undertaken. However, following disconnection of the

pump, glucose levels rapidly rose to between 20-25 mmol/L within 6 hours (capillary blood ketones were 0.4 mmol/L), insulin was therefore recommenced the following day.

Following discussion, a higher dose of glibenclamide was given (40mg three times daily – 2mg/kg/day) for several months, however, insulin was still required to maintain normoglycaemia. This was achieved through once-daily injections of long-acting insulin, enabling discontinuation of pump therapy. After commencement of glibenclamide, her HbA1c fell to 52 mmol/mol (6.9%) and her random C-peptide was 637 pmol/L (see table 1). Her hypoglycaemia awareness was also restored. Repeat CGM revealed some hypoglycaemia and her glargine dose was accordingly reduced. The standard deviation of blood glucose measurements was significantly lower (at 2.7 mmol/L) than before sulphonylurea therapy. She is currently maintained on 40mg glibenclamide three times daily and 10 units insulin glargine once daily, with no mealtime insulin bolus.

Functional studies

The latest crystal structure reveals that residue G334 forms part of the ATP-binding site and may reduce the ability of ATP to bind to Kir6.2, either by steric interference or electrostatic repulsion (11). We therefore first examined the sensitivity of wild-type (WT) and mutant channels to inhibition by MgATP. Figure (ESM) shows that WT channels were half maximally blocked (IC_{50}) by $20 \pm 1 \mu M$ MgATP ($n=7$). The ATP sensitivity of heterozygous (hetG334V) Kir6.2-G334V/SUR1 channels was significantly decreased ($IC_{50}=163 \pm 42 \mu M$, $n=6$; $p<0.01$ vs. WT) and that of homozygous (homG334V) channels was reduced even further ($IC_{50}=2.6 \pm 0.5 mM$, $n=3$). There was also a substantial increase in the current amplitude at physiological levels of MgATP: at 3mM, the percentage of unblocked current was $1.2 \pm 0.2\%$ ($n=7$) for WT, whereas it was $12 \pm 2\%$ ($n=6$) and $48 \pm 4\%$ ($n=3$) for hetG334V and homG334V, respectively. This increase in current can account for the diabetes in the presented case and demonstrates that the mutation is pathological.

We next analysed the effects of the Kir6.2-G334V mutation on the metabolic regulation and sulphonylurea sensitivity of the K_{ATP} channel by measuring whole-cell currents. When wild-type (WT) K_{ATP} channels are expressed in *Xenopus* oocytes they are normally closed, due to the high intracellular ATP concentration ($[ATP]_i$). However, they can be opened by lowering $[ATP]_i$ using a metabolic inhibitor such as Na-azide (figure 3a). Mutations that reduce the channel ATP sensitivity normally increase the whole-cell current in control solution, reflecting the fact that they are less blocked by resting $[ATP]_i$. Both hetG334V and homG334V currents were substantially larger than WT both in control solution (figure 3a), as expected from their lower ATP sensitivity. The sulphonylurea tolbutamide, at a dose that maximally inhibits the WT channels (0.5mM) blocked all three types of channel: by $97.2 \pm 0.3\%$ ($n=10$) for WT, $91 \pm 2\%$ ($n=6$) for hetG334V and $78 \pm 2\%$ ($n=7$) for homG334V (figure 3b). These results predict that the individual should be sensitive to

sulphonylurea therapy.

Discussion

We report a young woman with a *KCNJ11*-G334V mutation who, despite being unable to completely stop insulin, showed a significant improvement in glycaemic control when high dose sulphonylurea therapy was combined with insulin. It is noteworthy that this combination therapy also led to a marked improvement in glycaemic variability and in hypoglycaemia awareness. Furthermore, meal-time bolus insulin was no longer required.

The G334V mutation has been described in one previous case, a male individual, in whom complete transfer was also attempted, around 20 years post-diagnosis(8). Despite a rise in C-peptide concentration, insulin had to be recommenced after a 5-day trial of glibenclamide. The increase in C-peptide demonstrates that beta-cells were at least partially functional following K_{ATP} channel closure. Based on our results, it seems possible that the reported case could also have been managed on a combination of a low-dose insulin supplemented with sulphonylurea treatment. It is important to gradually titrate sulphonylurea doses over time to ascertain responsiveness, as demonstrated in our case, where starting doses of glibenclamide had little effect on glycaemia.

In vitro functional studies revealed the G334V mutation led to a small reduction in sulphonylurea sensitivity. However, the extent of block (91%) was well within the range predicted to enable complete transfer off insulin, based on previous findings (60-75% (4,6)) . That our case was unable to do so likely reflects the late age at transfer, as the transfer success rate declines with duration of diabetes (6,7). Approximately 30% of those over the age of 18 are unsuccessful, compared with <5% individuals with the same mutation under the age of 2 years. Rodent models suggest one reason for a better outcome when sulphonylurea is commenced early may be that beta-cell exposure to chronic hyperglycemia leads to loss of insulin content, impaired beta-cell metabolism-secretion coupling, and reduced beta-cell mass (12). Whilst it is possible that with further titration of glibenclamide, transition off insulin may be achieved, the 3-month trial at higher doses yielded no further reduction in insulin. Stopping insulin was characterised by fasting hyperglycaemia and so insulin was recommenced.

Sulphonylurea therapy led to a reduction in glycaemic variability and abolished the requirement for meal-time insulin. It is likely that both these effects result from restoration of the incretin response. Incretins are only effective when the K_{ATP} channels are closed, which leads to membrane depolarization, calcium influx and insulin release (13). Thus incretin-based drugs maybe of greater benefit when combined with sulphonylurea therapy.

It is possible that combination therapy would also be of benefit in people with mutations that have shown a reduced blockade in response to tolbutamide. Further studies are needed to explore this possibility.

Two studies have reported treatment outcomes on numbers of individuals with permanent neonatal diabetes. That by Thurber et al (7) reported that 2 out of 57 individuals remained on both insulin and sulphonylurea therapy. Babiker et al (6), defined successful transfer as the ability to stop insulin completely. Our study suggests that a reduction in insulin dose should also be considered a successful outcome as it is associated with clinical benefits. Indeed, although no clinical outcomes were reported, Babiker et al also recommended trialing combination therapy.

In conclusion, our data show that in people with *KNCJ11* mutations who are unable to completely transfer to sulphonylurea therapy, a combination of insulin and sulphonylurea treatment may be of clinical benefit, improving glycaemic control, hypoglycaemia awareness and glycaemic variability. Furthermore, there may be improvements in quality of life, for example by cessation of insulin pump therapy and managing mealtimes without bolus insulin. Thus, the inability to fully transfer off insulin should be still considered a valuable treatment in combination with sulphonylureas.

Addendum: while this paper was in review, a paper appeared reporting that 2 individuals who were initially managed solely on sulphonylurea therapy failed to retain good glycaemic control after several years, and in these people combination therapy did not produce better glycaemic control (14). This contrasts with our individual who showed an improved outcome, and may be related to diabetes duration or other factors.

Funding:

SM was funded by the Diabetes, Research and Wellness Foundation Sutherland Earl Clinical Research Fellowship whilst undertaking this work. ATH is a Wellcome Trust Senior Investigator. FMA holds a Royal Society/Wolfson Merit Award and an ERC Advanced Investigatorship.

Guarantor

FMA and NSO are the guarantors of this article.

Contributions

SM and NSO collected and analysed the clinical data. EDF undertook genetic testing. NV and EC collected and analysed the TEVC data, NV collected and analysed the patch-clamp data. SM, NV,

FMA, and NSO wrote the manuscript. All authors critically reviewed and revised the manuscript and approved the final version.

References

1. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. *Diabetologia*. 2006;49(6):1190–7.
2. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, et al. Permanent neonatal diabetes caused by dominant, recessive, or compound heterozygous SUR1 mutations with opposite functional effects. *Am J Hum Genet*. 2007;81(2):375–82.
3. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. *Diabetes*. 2005;54(9):2503–13.
4. McTaggart JS, Clark RH, Ashcroft FM. Symposium Review: The role of the KATP channel in glucose homeostasis in health and disease: more than meets the islet. *J Physiol*. Blackwell Publishing Ltd; 2010;588(17):3201–9.
5. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. *N Engl J Med*. 2006;355(5):467–77.
6. Babiker T, Vedovato N, Patel K, Thomas N, Finn R, Männikkö R, et al. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes. *Diabetologia*. 2016 Mar 31;59:1162–6.
7. Thurber B, Carmody D, Tadie E, Pastore A, Dickens J, Wroblewski K, et al. Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes. *Diabetologia*. Springer Berlin Heidelberg; 2015;58(7):1430–5.
8. Lau E, Correia C, Freitas P, Nogueira C, Costa M, Saavedra A, et al. Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea. *Arch Endocrinol Metab*. 2015;59(6):559–61.
9. Gribble FM, Ashfield R, Ammala C, Ashcroft FM. Properties of cloned ATP-sensitive K⁺ currents expressed in *Xenopus* oocytes. *J Physiol*. 1997;498 (Pt 1):87–98.
10. Hattersley A. Transferring patients with diabetes due to a KIR6.2 mutation from insulin to sulphonylureas: providing information for patients and professionals on research and clinical care in genetic types of diabetes. Available from www.diabetesgenes.org/content/tran. Accessed 30th June 2016.
11. Martin GM, Kandasamy B, DiMaio F, Yoshioka C, Shyng S-L. Anti-diabetic drug binding site in a mammalian KATP channel revealed by Cryo-EM. *Elife*. England; 2017 Oct;6.
12. Brereton MF, Iberl M, Shimomura K, Zhang Q, Adriaenssens AE, Proks P, et al. Reversible changes in pancreatic islet structure and function produced by elevated blood glucose. *Nat Commun*. Nature Pub. Group; 2014 Aug 22;5:4639.
13. Henquin JC. Regulation of insulin secretion: a matter of phase control and amplitude

- modulation. *Diabetologia*. Germany; 2009 May;52(5):739–51.
14. Stanik J, Dankovcikova A, Barak L, Skopkova M, Palko M, Divinec J, et al. Sulfonylurea vs insulin therapy in individuals with sulfonylurea-sensitive permanent neonatal diabetes mellitus, attributable to a KCNJ11 mutation, and poor glycaemic control. Vol. 35, *Diabetic medicine : a journal of the British Diabetic Association*. England; 2018. p. 386–91.

Table 1. Clinical and biochemical data before and after commencement of sulphonylurea therapy.

	Before	After
HbA1c mmol/mol [%]	88 [10.2]	52 [6.9]
Random C-peptide (pmol/L)	11	637
Paired random glucose mmol/L	9.3	6.9
Total insulin dose in 24 hours	80-85 units	10 units
Glibenclamide dose	-----	40 mg three times daily (2mg/kg/day)
Weight (kg)	59	53

Figure Legends

Figure 1. C-peptide (grey line), insulin (dash line) and glucose (black line) levels during an oral glucose tolerance test (OGTT). Glucose was given at time zero. A dose of 5mg glibenclamide plus 15units insulin was given at t=150 minutes with lunch. Note the marked increase in C-peptide after glibenclamide.

Figure 2. Changes in glibenclamide dose (grey line), median blood glucose (black line) and daily basal insulin (dashed line) dose during glibenclamide dose titration. Note changes in glycaemia with higher doses of glibenclamide not observed at lower doses.

Figure 3. Metabolic sensitivity of the wild-type and mutant K_{ATP} channel.

(a) Whole-cell currents were measured in oocytes expressing wild-type (WT; n=10), heteromeric (hetG334V; n=7) or homomeric (homG334V; n=6) K_{ATP} channels. The currents were recorded in control solution (black bars), after metabolic inhibition with 3 mM sodium azide (white bars) and after the further addition of 0.5mM tolbutamide (tolb, grey bars). **(b)** Mean $\pm$ SEM tolbutamide block for WT (n=10) and hetG334V (n=6) channels, compared to the mean value for permanent neonatal diabetes mutant channels (n=19 mutations). Tolbutamide block is expressed as the percentage block of the azide-induced current.

Supplementary material

Figure S1. The G334V mutation reduces ATP inhibition of the K_{ATP} channel. MgATP concentration-response relations for wild-type (WT, filled square), homomeric G334V (homG334V, filled circle) and heteromeric (hetG334V, empty circle) K_{ATP} channels. The curves are the best fit to the Hill equation.